Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA Read more about Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA
World's Largest Alzheimer's Survey Reveals Most Adults Believe a Cure Will be Developed in Their Lifetime Read more about World's Largest Alzheimer's Survey Reveals Most Adults Believe a Cure Will be Developed in Their Lifetime
Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference Read more about Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
Amgen To Present At The Morgan Stanley Global Healthcare Conference Read more about Amgen To Present At The Morgan Stanley Global Healthcare Conference
Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype Read more about Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype
Amgen And LabCentral Open Nomination Process For Lab Residency Read more about Amgen And LabCentral Open Nomination Process For Lab Residency
European Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Read more about European Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone Read more about Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
Amgen To Present Robust Data Exploring The Impact Of Treatment With Repatha® (evolocumab) Across Patient Subgroups And High-Risk Populations At ESC Congress 2018 Read more about Amgen To Present Robust Data Exploring The Impact Of Treatment With Repatha® (evolocumab) Across Patient Subgroups And High-Risk Populations At ESC Congress 2018
